AutoMVA

About this project

<p><span style="font-size: 11pt"><span style="color: #000000">The global market demand for biomarkers research has been increasing in the recent years due to the rapid world population growth. This has resulted in a larger number of organizations researching biomarkers. The advancements and innovations of biomarkers research have made it possible to utilize biomarkers use in detecting diseases and cures. Considering its immense potential, immunoprofiling is forecasted to become an essential tool in precision medicine, to help improve the efficiency of drugs by selecting patients exhibiting a good response and to assess the immune status of the patient. </span></span></p> <p><span style="font-size: 11pt"><span style="color: #000000">The main objective of the development project is to develop automated data analysis platform to reduce time and costs needed for biomarker identification and validation. Automation of the antibody profile analysis would revolutionize immune screening like next generation sequencing revolutionized DNA analysis. The platform would substitute current data analysis processes which is very time-consuming and inefficient. Currently collecting, cleaning and analysing the data requires a lot of manual operations and could only be carried out by specialists with very specific knowledge. </span></span></p> <p><span style="font-size: 11pt"><span style="color: #000000">The automated data analysis platform would enable to predict early stage type 2 diabetes by utilizing immunoprofiling based disease and health risk diagnostics solution developed by IPDx. <span style="font-size: 11pt"><span style="color: #000000">The platform would substitute current data analysis processes which is very time-consuming and inefficient. It could take as long as up to a month, for a researching company to detect the biomarkers. IPDx is in the development process of an MVA automation system, that would reduce the biomarkers detection time 10 times. </span></span></span></span></p> <p><span style="font-size: 11pt"><span style="color: #000000">The Norwegian partner engaged in this development project is Oslo University Hospital whose primary role is to collect blood samples from type 2 diabetic patients and to provide expert scientific input into the analysis of the results. </span></span></p>

Bilateral cooperation results

The partnership worked smoothly, although the role of the Norwegian partner turned out to be smaller than originally planned. The partner was mainly involved in the analysis of samples. At the same time, the partner was very helpful in organising brainstorming sessions, which, unfortunately, is not directly reflected in the project costs.

Project partners

• University Hospital Oslo/Cancer Registry of Norway Donor project partner· Norway